Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

1. Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.PloS one · 2026
   Trial
2. A stepwise institutional approach to refractory autoimmune cytopenia after allogeneic stem cell transplantation in children: a retrospective case series.Frontiers in immunology · 2026
   Article
3. Nonmyeloablative Pentostatin-Cyclophosphamide Preconditioning Improves Rates of Engraftment in Adults Undergoing Haploidentical HCT for Sickle Cell Disease.medRxiv : the preprint server for health sciences · 2025
   Article
4. Incidence, Risk Factors, and Treatment of Autoimmune Cytopenia Following Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.Journal of transplantation · 2025
   Article
5. Autoimmune Hemolytic Anemia: A Challenging Complication of Allogeneic Hematopoietic Stem Cell Transplant.Cureus · 2024
   Article
6. Autoimmune cytopenias following pediatric hematopoietic cell transplant.Bone marrow transplantation · 2024
   Article
7. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.Transplantation and cellular therapy · 2022
   Review
8. TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders.Blood advances · 2022
   Article
9. Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant.Pediatric blood & cancer · 2022
   Article
10. Autoimmune Cytopenias Post Hematopoietic Stem Cell Transplantation in Pediatric Patients With Osteopetrosis and Other Nonmalignant Diseases.Frontiers in immunology · 2022
    Article
11. Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.Bone marrow transplantation · 2021
    Review
12. Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature.Molecular and cellular pediatrics · 2021
    Article
13. Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs).Hematology. American Society of Hematology. Education Program · 2020
    Review
14. Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.International journal of molecular sciences · 2020
    Article
15. Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives.Journal of blood medicine · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as